Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29639045 | 0.81 | HTT (0.36) | AHRCSNK2A1CDK1NPC1RAB9A | |
| SCHEMBL1258350 | 0.81 | CDK1 (0.48) | AHRCASP6MAPK13CDK1PIM1 | |
| SCHEMBL18388861 | 0.81 | HTT (0.36) | AHRCSNK2A1CDK1NPC1RAB9A | |
| SCHEMBL16636981 | 0.76 | PRKCI (0.41) | AHRCSNK2A1CYP1A2HTTNR4A2 | |
| SCHEMBL28370443 | 0.74 | CASP6 (0.62) | CASP6MMP2NPC1RAB9ACYP1A2 | |
| SCHEMBL22659050 | 0.74 | CASP6 (0.58) | CASP6MMP2NPC1RAB9ACYP1A2 | |
| SCHEMBL2594620 | 0.73 | AHR (0.44) | AHRCSNK2A1MAPK13CDK1PIM1 | |
| SCHEMBL21050938 | 0.72 | KMT2A (0.39) | CYP1A2HTTNR4A2MEN1POLB | |
| SCHEMBL28995880 | 0.72 | SMN1; SMN2 (0.41) | NPC1RAB9AHCAR1CYP1A2HTT | |
| SCHEMBL18451242 | 0.72 | KMT2A (0.39) | CSNK2A1CYP1A2HTTNR4A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101436-A1 | APTAMERS AND SMALL MOLECULE LIGANDS | MeiraGTx Gene Regulation Limited (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-4448769-A2 | APTAMERS AND SMALL MOLECULE LIGANDS | Meiragtx UK II Limited (GB) | 2024-10-23 | — | — | EP | disclosed |
| CN-118786217-A | Aptamer and small molecule ligand | 梅里特斯英国第二有限公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2023111686-A2 | APTAMERS AND SMALL MOLECULE LIGANDS | MEIRAGTX UK II LIMITED (GB) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023111686-A2 | APTAMERS AND SMALL MOLECULE LIGANDS | MEIRAGTX UK II LIMITED (GB) | 2023-06-22 | — | — | WO | disclosed |
| CN-102197031-A | Substituted 5-aminopyrazoles and use thereof | BAYER SCHERING PHARMA AG | 2011-09-21 | — | — | CN | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101436-A1 | APTAMERS AND SMALL MOLECULE LIGANDS | RNGTT, SLIRP, SNRPE | AHR 2544/4885CSNK2A1 4186/4885CASP6 2710/4885 |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | AHR 617/4885CSNK2A1 3313/4885CASP6 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.